Clinical effect of combination of Liuweiwuling tablets and thymopentin on liver fibrosis

Objective To explore the clinical effect of Liuweiwuling tablets and thymopentin for chronic hepatitis B cases with liver fibrosis. Methods Total of 72 chronic hepatitis B cases with liver fibrosis were randomly divided into control group (34 cases) and treatment group (38 cases). Treatment group were treated with Liuweiwuling tablets combined with thymopentin. Control group were treated with thymopentin only. The course of treatment were 12 weeks, as well as the course of following-up visit. Liver functions, liver fibrosis indexes and liver fibrosis noninvasive value of both groups were measured after therapy and the results of the two groups were compared. Results Liver function recovery rate and serum liver fibrosis indexes were significantly improved in both groups, compared with before treatment (all P 0.05). And there were significant differences between the two groups after treatment (P 0.05). Liver fibrosis noninvasive value of both groups decreased significantly after treatment. Conclusions Liuweiwuling tablets combined with thymopentin is effective and safe in the treatment of liver fibrosis after chronic hepatitis B. It can improve liver function and inhibit the progress of liver fibrosis.